Embolx, Inc. – FDA 483, Jan 19, 2023
Embolx, Inc. in Sunnyvale, CA, a specification developer, received a Form 483 with six observations primarily concerning deficiencies in their quality system. Key issues include inadequate medical device reporting procedures, incomplete complaint investigation records, insufficient CAPA documentation and effectiveness checks, and failures in management review, quality audits, and supplier evaluation processes. The observations indicate systemic issues in maintaining an effective quality system.
ID · 49a0adac-d7b2-4906-b611-90d855f6bf9b
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.